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Abstract
Background: Dietary nucleotide supplementation has been shown to have important effects on the
growth and development of cells which have a rapid turnover such as those in the immune system and the
gastrointestinal tract. Work with infants has shown that the incidence and duration of diarrhoea is lower
when nucleotide supplementation is given, and animal work shows that villi height and crypt depth in the
intestine is increased as a result of dietary nucleotides. Dietary nucleotides may be semi-essential under
conditions of ill-health, poor diet or stress. Since people with Irritable Bowel Syndrome tend to fulfil these
conditions, we tested the hypothesis that symptoms would be improved with dietary nucleotide
supplementation.
Methods: Thirty-seven people with a diagnosis of Irritable Bowel gave daily symptom severity ratings for
abdominal pain, diarrhoea, urgency to have a bowel movement, incomplete feeling of evacuation after a
bowel movement, bloating, flatulence and constipation for 28 days (baseline). They were then assigned to
either placebo (56 days) followed by experimental (56 days) or the reverse. There was a four week
washout period before crossover. During the placebo and experimental conditions participants took one
500 mg capsule three times a day; in the experimental condition the capsule contained the nutroceutical
substances. Symptom severity ratings and psychological measures (anxiety, depression, illness
intrusiveness and general health) were obtained and analysed by repeated measures ANOVAs.
Results: Symptom severity for all symptoms (except constipation) were in the expected direction of
baseline>placebo>experimental condition. Symptom improvement was in the range 4 – 6%. A feeling of
incomplete evacuation and abdominal pain showed the most improvement. The differences between
conditions for diarrhoea, bloating and flatulence were not significant at the p < .05 level. There were no
significant differences between the conditions for any of the psychological measures.
Conclusion: Dietary nucleotide supplementation improves some of the symptoms of irritable bowel
above baseline and placebo level. As expected, placebo effects were high. Apart from abdominal pain and
urgency to have a bowel movement, the improvements, while consistent, are modest, and were not
accompanied by improvements in any of the psychological measures. We suggest that the percentage
improvement over and above the placebo effect is a physiological effect of the nucleotide supplement on
the gut. The mechanisms by which these effects might improve symptoms are discussed.
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Background
Irritable Bowel Syndrome (IBS) is a chronic disorder
affecting an estimated 15 – 22% of western populations,
and is the major cause of referrals to gastroenterology clin-
ics in the western world [1]. The symptoms may include
abdominal pain, diarrhoea, urgency to have a bowel
movement, a feeling of incomplete evacuation after a
bowel movement, flatulence and bloating. Some sufferers
experience constipation, or an alternation between consti-
pation and diarrhoea. IBS is more common among
women than men, with a 2:1 female: male ratio [2]. Cur-
rent medical treatments are directed at symptomatic relief,
and although these can give some relief, there is no one
treatment which has been shown to be lastingly effective.
Although IBS is not a life-threatening disease, the symp-
toms and the effects of the symptoms on daily life can
have a great impact on sufferers [3]. IBS is also associated
with large healthcare and economic costs in terms of hos-
pital investigations, repeated visits to GPs, prescription
medicines, and loss of time from work [4]. Although hos-
pital investigations for more serious diseases such as can-
cer or Inflammatory Bowel Disease are negative in people
with IBS, some abnormalities in the gut have been found.
For instance, some patients have been found to have a
degree of mucosal inflammation, which may be in
response to some foods [5]. It is possible that people with
IBS have immunological reactions to dietary antigens as
food elimination based on serum immunoglobulin G
antibodies has been found to result in a significant
decrease in symptoms of IBS. Both numbers of mast cells
and their mediators have been shown to be increased in
intestinal mucosa in patients with irritable bowel syn-
drome, especially in the close proximity of intestinal
nerves [6]. Kalliomäki [6] suggests that food antigens
induce mast cells to secrete mediators which regulate gas-
trointestinal motility, resulting in alterations in peristalsis
and an increase in abdominal pain and discomfort. Fur-
thermore, the mast cell-derived mediators have effects on
immune cell functions. It may be then, that the nutrition
of people with IBS is more important than has been tradi-
tionally thought. As people with IBS tend to believe that
their symptoms are affected by diet, they often attempt to
manage their disorder by dietary control. However, the
only consistent advice given to people with IBS is usually
simply to eat a "healthy" diet which includes fruit, vegeta-
bles and fibre. In an early study of people with IBS,
Dancey & Backhouse [7] found that although the majority
of their sample of 148 people (70%) stated that they were
trying to follow a "healthy" diet with large amounts of
fruit and vegetables; for many of these people, such a strat-
egy had not led to symptom improvement, and in an
attempt to control their IBS, 14% were eating very
restricted diets. Some of these diets involved avoiding
complete groups of foods, e.g. carbohydrates. Whilst such
a strategy may reduce bloating, for instance, such a diet is
not likely to enhance wellbeing. As well as eating a suffi-
cient quantity of a wide variety of foods from each food
group, micronutrients and nucleotides may also be
important for health, especially in the sub-well. It is nucle-
otides which are the focus of this study.
Nucleotides are substances which are synthesised endog-
enously – they have important effects on the growth and
development of cells which have a rapid turnover, such as
those in the immune system and the gastrointestinal tract.
The intestinal epithelium is a rapidly proliferating tissue
with a high cellular turnover rate. A complete cell cycle in
humans is 24 hours, with a replacement of the entire
enteric epithelium within 3–6 days. In healthy people,
dietary nucleotides are probably not essential, and in fact
most will be metabolised and rapidly excreted from the
system. However, under certain circumstances (e.g. in the
sub-well, diseased, or under conditions of stress or poor
diet) dietary nucleotides may be what Maldonado,
Navorro, Narbona, & Gil [8] call "semi-essential", opti-
mising the function of the gastrointestinal and immune
systems. In relation to the gastrointestinal system work
has shown that dietary nucleotides enhance the intestinal
absorption of iron [9]. Dietary sources of nucleotides are
nucleoproteins and nucleic acids, and these are found to
varying degrees in many foods – lamb, liver, mushrooms
(but not fruit and other vegetables) all are rich in nucle-
otides. Rapidly dividing tissue requires a constant supply
of nucleotides in order to manufacture essential nucleic
acids. Exogenous supplies of nucleotides may optimise
tissue function particularly during recovery from mucosal
injuries when the endogenous supply may limit the syn-
thesis of nucleic acids.
Holen & Jonsson [10] found that dietary nucleotides had
beneficial effects, especially when the nutrition supply
was inadequate. Work with infants has shown that the
incidence and duration of acute diarrhoea is lower in
infants when dietary nucleotides are included in their
diets [11]. Previous work on the effect of nucleotide sup-
plementation in animals has found that such supple-
ments are important for the repair mechanism of immune
cells [12]. In piglets, nucleotide supplementation had
effects on the gastrointestinal system by increasing villi
height and crypt depth. [13]. Evans, Tian, Gu, Jones & Zie-
gler [14], using rats to model short-bowel syndrome,
found that nucleotide supplementation is associated with
increased jejunal adaptive growth after massive small
bowel resection in rats. Dietary nucleotides have been
found to help athletes by reducing the release of stress
related hormones and chemicals in the body, and by
maintaining a higher level of antibodies, which enables
the immune system to work more effectively [15]. In peo-
ple with a chronic illness such as IBS whose primary
symptoms relate to the gastrointestinal tract, nucleotideNutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
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supplementation may improve symptoms via improved
gut function or by an enhancement of the immune sys-
tem.
There are particular problems in assessing the benefits of
treatments of people with IBS, and some of the problems
of this patient group in relation to clinical trials have been
discussed in detail by Spiller [16]. People with IBS show
great variability in frequency and severity of symptoms,
both when compared to others and also from day-to-day
in their own symptoms. Spiller [16] has shown there are
clear benefits to participating in clinical trials; people with
IBS tend to be helped by placebo alone. This is thought to
be due to a reduction in anxiety and/or depression as a
result of help and reassurance given by the people running
the trial. If this is the case, then anxiety and depression
should reduce over the length of the trial. One would also
expect that, if symptoms improve, then psychological
well-being should in some way improve also. Thus
although our primary aim was to determine whether
nucleotide supplementation improved the symptoms of
irritable bowel, we also wished to determine whether rat-
ings of anxiety and/or depression would show any change
as a result of symptom change.
Methods
Design
A double-blind randomised placebo cross-over study in
which participants rated symptoms daily for six months in
baseline, placebo, and experimental conditions. This
study was approved by our university ethics committee
and was in accordance with the code of conduct for psy-
chologists (ethical principles for conducting research with
human participants) produced by the British Psychologi-
cal Society. The research was conducted only when written
consent was received from the participant, and their G.P.
had provided written confirmation of their diagnosis, and
confirmation of no other co-existing conditions.
Participants
Thirty seven people with a diagnosis of Irritable Bowel
Syndrome took part in the study. The inclusion criteria
were that participants should be aged 18 – 65, should
have been diagnosed as having IBS by a qualified medical
practitioner, and should have diarrhoea as a main symp-
tom. The exclusion criteria were any other co-existing ill-
nesses, and non-confirmation of the diagnosis by G.P. The
participant flow is shown below (see Figure 1).
Thirty-seven participants completed the trial, during
which they completed daily symptom diaries for four
weeks (baseline) following by either the experimental
condition (eight weeks) or the placebo condition (eight
weeks). There was a four week washout period between
conditions. The mucosal cell turn-over for the whole tract
is approximately six days, with the majority of other cells
in the body are also replaced over 30 days. For this reason
a 30 day washout was selected. Although some of the par-
ticipants rated some symptoms as not particularly bother-
some over the baseline condition no person was excluded
by us.
IBS symptoms
The symptoms of interest were: abdominal pain, diar-
rhoea, urgency to have a bowel movement, incomplete
evacuation after a bowel movement, flatulence, bloating,
and constipation. Participants rated symptoms every day
on a scale of 1 ("no discomfort at all today") to 7 ("very
severe discomfort today"). Reliability for these symptoms
has been previously established [17].
Participants were given a pack containing a month's sup-
ply of daily diaries in which to record their symptoms. The
next month's supply were sent to the participants once the
previous completed pack had been returned.
Neutroceutical product
Participants took one 500 mg capsule three times a day
with meals – in the experimental condition these con-
tained the neutroceutical product IntestAidIB which con-
sists of the following active substances: nucleotides &
RNA (concentrated extracts of Saccharomyces cerevisae),
hydroxypropyl methycellulose, FOS (fructo-olligosaccha-
rides), Methionine, Glutamine, Inositol, Lysine, Pan-
tothenic acid (Vitamin B5 as Calcium d-pantothenate),
Sodium citrate, Riboflavin (Vitamin B2), Vanillin, Folic
acid, and Biotin. Flow agents are magnesium stearate and
silicic acid. The capsules are carbohydrate based. RNA and
the specific, purified nucleotides are the natural extracts of
yeast. There are no yeast cells carried over from the extrac-
tion process into the product. The daily diaries contained
space where participants confirmed that they had taken
each capsule, and at what time of day.
Procedure
Recruitment was by a variety of sources. Notices asking for
people with diagnosed IBS interested in taking part in a
trial for a neutroceutical product were sent to people with
IBS who had previously expressed an interest in IBS-
related research; a request was included in one issue of
Gut Reaction (a quarterly journal sent to people with IBS
by The IBS Network, a British self-help organisation), and
notices were placed in doctors' surgeries and libraries.
Such a recruitment strategy was considered necessary, as
strict inclusion and exclusion criteria, plus the burden of
completing daily diaries for six months meant recruit-
ment might be difficult. We wished to have a mixed group
of people with IBS, representative of the general popula-
tion of people with IBS. Recruiting from tertiary centresNutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
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does not allow generalisation to the wider population of
people with this condition.
Participants were invited to respond to these recruitment
methods by telephone or e-mail. During this initial con-
participant flow through the trial Figure 1
participant flow through the trial.Nutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
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tact, the researcher ensured that potential participants met
the inclusion criteria. Eligible individuals were then given
full information relating to the study. They were advised
at this stage of their right to withdraw their participation
and/or any data already provided, at any time, without
giving any notice or reason to the research team.
Participants were then asked to provide contact details for
their GP, and a consent form was sent by post to the par-
ticipant for them to complete and return, as well as a pack
providing further information about the trial and the sup-
plement. Their GP was also sent a letter at this point, sum-
marising the trial and requesting confirmation of
diagnosis. Upon receipt of the confirmation of diagnosis
and participant consent forms, participants were ran-
domised to each of the conditions.
Initially participants were sent their first symptom diary
pack, which contained detailed instructions on how to
complete the diary as well as the first diary itself. The diary
required participants to rate the severity of their symp-
toms (see above) and to specify the times at which they
had taken each of their three capsules; to name any med-
ications which they were prescribed, had purchased
(including price) and had actually taken (including time
taken) that day; and to note any visits to health profes-
sionals made that day (including who they visited, reason
for visit and advice given).
Participants were contacted by telephone or e-mail a week
after this first pack was sent out (week 1), to confirm that
they understood how to complete the questionnaires and
the diary. Participants were sent their first set of capsules
(a "set" comprised four sealed tubs) – all tubs were
marked "nutritional supplement, contents 42 capsules
(500 mg), two weeks supply", but with A or B clearly
marked both on the label and on the cap) one week before
they were to need them (week 3), with a letter stating the
date on which they should begin taking the capsules. They
were contacted by telephone or e-mail a few days after this
date (week 5) to ensure that they were taking the capsules
at the right dosage (one capsules three times a day, prefer-
ably with meals), that they were completing the symptom
diary with the required information (time capsules taken,
any missed capsules noted), and that they were aware of
how to contact the research team if they had concerns
about any effect which the capsules may have upon them.
Following this, participants were sent a symptom diary
pack every month, their second set of capsules for week
17, a set of questionnaires (described below) at week 13
and week 25. All documentation and capsules were sent
one week before they were required to ensure that they
arrived in good time. Every letter sent to the participants
included contact details for the research team and urged
participants to telephone or e-mail with any questions or
worries, at any stage of the trial. Participants were sent
questionnaire packs at baseline, washout, and end of trial.
Every participant forgot to take at least one capsule across
the duration of the trial, but this was usually one capsule
only on any given day. There were two exceptions – one
participant took capsules erratically over the last six weeks
of the experimental condition and after the first five weeks
of the placebo condition. This participant had a change of
personal circumstances during this time (she underwent a
hysterectomy). The other participant took no capsules for
5 days in the last week of the experimental condition as
she went away and forgot to take the capsules with her.
Psychological measures
Measures were taken at the beginning of the baseline
period, the end of the experimental condition and the end
of the placebo condition.
Depression was measured by the CES-D [18] and anxiety
was measured by the Stait-Trait Anxiety inventory [19]; a
specific measure of health anxiety was provided by the
Health Anxiety Questionnaire [20]. General health and
happiness were measured by the total of the GHQ-60 [21]
and the Affect Balance Scale [22]. The extent to which IBS
intrudes into various aspects of everyday life was meas-
ured by the 13-item Illness Intrusiveness Rating Scale [23].
Results
The average person with IBS spent approximately £15.00
during the six months trial on medications, supplements,
minerals and vitamins and visited the G.P.'s surgery
approximately seven times, the majority of the consulta-
tion times being for reasons other than IBS.
Symptoms
For symptom recording, three participants had some
sequential data missing, i.e. for the first participant this
was for seven days in the experimental condition; for the
second it was three days in the experimental condition,
and for the third, three days during baseline. For each
missing data point frequency data were obtained for the
particular condition in which the missing data occurred,
and the most appropriate (representative) measure of cen-
tral tendency was inserted.
Analysis of symptoms
Mean ratings for the symptom series for each condition
with 95% C.I.'s for the symptoms are represented below
(see Figure 2).
A repeated measures ANOVA on each of the symptoms
was carried out. Sphericity was not assumed and therefore
the Greenhouse-Geisser correction for degrees of freedomNutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
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was used. The difference between conditions for abdomi-
nal pain (F2,67 = 3.71; Eta2 = .10), urgency to have a bowel
movement (F2,64 = 3.82; Eta2  = .10) and a feeling of
incomplete evacuation (F = 2,67 = 3.52; Eta2 = .09) were sig-
nificant at p < .05. Diarrhoea (F2,58 = 3.08; Eta2 = .08), Flat-
ulence (F2,70 = 2.89; Eta2 = .07), Bloating (F2,68 = 2.61;
Eta2= .07) and Constipation (F2,49 = .31; Eta2 = .01) were
not statistically significant at p < .05.
The percentage improvement of both placebo and
IntestAidIB over baseline is shown below (see Figure 3).
Symptom severity for all symptoms (except constipation)
are in the expected direction of baseline>pla-
cebo>IntestAidIB.
Psychological measures
Repeated measures ANOVA were carried out on the psy-
chological variables. There were no significant differences
between conditions on these measures (p > .05).
It might be expected that due to the benefits of being in a
clinical trial, anxiety and depression would decrease over
mean symptom severity ratings with 95% C.Is Figure 2
mean symptom severity ratings with 95% C.Is.Nutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
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bar chart showing percentage change from baseline to placebo and experimental conditions Figure 3
bar chart showing percentage change from baseline to placebo and experimental conditions.Nutrition Journal 2006, 5:16 http://www.nutritionj.com/content/5/1/16
Page 8 of 9
(page number not for citation purposes)
time. We thus tested this by a repeated measures analysis
for CES-D and Health Anxiety and Stait-Trait Anxiety
comparing measures at baseline, washout and end of trial
without considering condition (placebo or experimental).
None of these measures were statistically significant (all p
> .05)
Discussion
The study has shown that there is a consistent improve-
ment in most of the symptoms of irritable bowel syn-
drome following nucleotide supplementation with
IntestAidIB. There was a very low drop-out rate (18%);
none of the participants who completed the study
reported any side-effects. A feeling of urgency to have a
bowel movement and abdominal pain showed the most
improvement over baseline and placebo, and since
abdominal pain is the symptom most likely to prompt
people to seek medical help, this is a important finding. A
feeling of incomplete evacuation after a bowel movement
also improved following treatment by the neutroceutical
product. However, whilst statistically significant,
improvements are modest, and this may be due to several
factors. Firstly, people with IBS are not a homogenous
group, and show great variability in frequency and sever-
ity of symptoms, both from each other, and individually.
This makes it difficult to detect effects of interventions.
Secondly, the placebo response was strong – Spiller [16]
states that it takes approximately 12 weeks for the placebo
effect to reduce. Perhaps a longer trial – and with a larger
dose – effects might have been stronger. However, this is
speculative and further trials need to take these factors
into consideration.
Participants were a mixed group of people who have a cur-
rent diagnosis of IBS, some of whom still attend a gastro-
enterological clinic, and some of whom do not. They were
not obtained from tertiary centres and carried on with
their normal life taking their usual medications. Although
their symptoms were not perhaps as severe as tertiary
patients, their symptoms were bothersome enough for
them to enter the clinical trial, and the symptoms were
severe enough for the participants to buy a range of prod-
ucts aimed at relieving their symptoms. We expect that the
effects found in this simple would be stronger if replicated
with participants from tertiary centres.
The benefits over placebo compare favourably with bene-
fits found in some drug trials. For example, Tegaserod (a
drug which acts as a selective agonist at 5HT receptors in
the gastrointestinal tract) was found to produce 4.7%
advantage over placebo in the participants' assessment of
global relief of IBS [24]. Although many such drugs are
well tolerated, there were no side effects at all reported in
the present study, which is a considerable advantage. The
percentage improvement varied according to the symp-
toms – between 4 and 6%. The symptom improvements
shown are unlikely to be the result of a decrease in anxiety
or depression which has sometimes been cited as a reason
for any improvement in trials, as anxiety and depression
in the present study did not decrease significantly as the
trial progressed (irrespective of condition). The effect – at
least at this dosage – does not seem strong enough to lead
to an improvement in psychological state since depres-
sion, anxiety, general health and illness intrusiveness did
not differ between the conditions.
The strong placebo effects found in the present study are
similar to those in other IBS- studies [16]. We suggest that
the percentage improvement over and above the placebo
effect is a physiological effect of the nucleotide supple-
ment on the gut. However, whilst results were consistent
and some symptoms were statistically significant, these
effects may not be strong enough to be perceived as a great
improvement by the participants, who will try to assess
the benefits of such a supplement against a background of
extremely variable symptoms. The mechanism by which
nucleotide supplementation might improve gut function
could be via increased mucosal protein, DNA and villus
height – as has been found in animal studies [14,25]
Evans et al [14] state that rodent models are useful in
translational research to identify potential new treatments
to increase gut mucosal growth that is potentially relevant
to humans with short bowel syndrome (this is not related
to IBS). They state "...an increase in the surface area that
would correlate with the increased villus height and crypt
depth may conceivably correspond to an increase in avail-
able nutrient transporters, which may translate into
increased nutrient uptake" (Although people with IBS
have not been shown to have damage to the gut, nucle-
otide supplementation may improve gut function none-
theless by such a mechanism. However, this is purely
speculative, and the present study set out only to deter-
mine whether symptoms of IBS were improved with
nucleotide supplementation. Further studies, preferably
dose-dependent studies, will need to be carried out to
determine the mechanism by which any improvements
occur.
Conclusion
A neutroceutical product, IntestAidIB, was found to
improve six of the measured seven symptoms of IBS com-
pared to both baseline and placebo. However, only
abdominal pain and urgency to have a bowel movement
showed statistically significant effects at the p < .05 level.
Although the improvements in symptoms were consist-
ent, the effects were not strong, and psychological meas-
ures showed no improvement either as a result of the
experimental condition, or due to the benefits of taking
part of a clinical trial. Further studies need to replicate andPublish with BioMed Central    and   every 
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extend these results, seeking to clarify the mechanism by
which improvements occur.
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